Ko te R&D a Sorrento e arotahi ana ki te akiaki i nga mahi hou i roto i te COVID-19, te maimoatanga mate pukupuku, te whakahaere mamae katoa me nga mate autoimmune.

Papatono Matua	Whakaatu	Tuhinga o mua	Wahanga I	Wahanga II	Wāhanga III/Pivotal	Whakaaetanga FDA
Kaupapa COVID-19
COVISTIX™ (tātari) Whakamātautau Antigen Tere 0%* Whakaaetanga Whakamahi ohorere (EUA) i Mexico (COFEPRIS), Brazil (ANVISA), me te tohu CE i Uropi COVIMARK™ (tātari) Whakamātautau Antigen Tere 0%* Tono i tukuna i te US me Kanata mo te Whakaaetanga Whakamahi ohorere (EUA) VIREX (tātari) I te Whare Taonga 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS na te COVID-19 i roto i nga turoro ICU 82%* Whakamātautau Pivotal i Brazil                           OVYDSO (Olgotrelvir) Anati-mate (Pire-waha) 40%* Omicron mRNA Vaccine kano 20%*
Papatono Matua	Whakaatu	Tuhinga o mua	Wahanga I	Wahanga II	Wāhanga III/Pivotal	Whakaaetanga FDA
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Lymphomas Pūtau 60.2%* FUJOVEE™ (Abivertinib) Patohi 20%* PD-L1 (Socazolimab)* SCLC 82%* *Ma te mahi tahi me Lee's Pharm i Haina PD-L1 (STI-3031)** He mate pukupuku 82%* **I US me te mahi tahi me ImmuneOncia i Korea CD47 Nga pukupuku totoka 40%* CD38 DAR-T Te maha o te taurua 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, me te esophageal 40%* TROP2 ADC* Nga pukupuku totoka 40%* Seprehvec™ huaketo oncolytic Nga pukupuku totoka; Nga pukupuku CNS 40%* BCMA ADC Nga Pumo Wai 20%* Bevacizumab-ADNAB™ Te mate pukupuku Endometrial 40%* I roto i te mahi tahi me Mayo Clinic Bevacizumab-ADNAB™ Ko te mate pukupuku ovarian 40%* I roto i te mahi tahi me Mayo Clinic Rituximab-ADNAB™ Lymphomas pūtau-B 40%* I roto i te mahi tahi me Mayo Clinic Sofusa® anti-PD-1 Putau T-Cell Lymphoma (CTCL), Melanoma 40%*
Papatono Matua	Whakaatu	Tuhinga o mua	Wahanga I	Wahanga II	Wāhanga III/Pivotal	Whakaaetanga FDA
Pain
ZTlido® 1.8 orau Neuralgia Postherpetic - PHN 99.8%* Gloperba® Te maimoatanga o te kauti (waha) 99.8%* SEMDEXA (SP-102) Te mamae o te Lumbar Radicular / Sciatica 82%* SP-103 (Lidocaine Topical System 5.4%) Te mamae o muri 60.2%* SP-104 (Naltrexone Te Putanga Iti Te Putanga) Fibromyalgia 20%* RTX (resiniferatoxin) Werohia epidural Te mamae i roto i te mate pukupuku matatau 60.3%* Te ingoa pani RTX (resiniferatoxin) Te ara-a-roto Te mamae o te turi ki te kino OA 60.2%*
Papatono Matua	Whakaatu	Tuhinga o mua	Wahanga I	Wahanga II	Wāhanga III/Pivotal	Whakaaetanga FDA
Te Tukunga Rongoa Lymphatic
Sofusa® anti-TNF Aunoa (RA) 40%* Sofusa® anti-PD-1 Putau T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* I roto i te mahi tahi me Mayo Clinic

Kaupapa COVID-19
Papatono Matua (tohu)	Waahi
COVISTIX™ (tātari) FDA EUA COVIMARK™ (tātari) FDA EUA VIREX (tātari) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Vaccine Tuhinga o mua

immunotherapy
Papatono Matua (tohu)	Waahi
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Tuhinga o mua PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Tumu totoka) Ph I CD38 DAR-T (Maamaa Maha) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, me te esophageal) Ph I TROP2 ADC* (Tumu totoka) Ph I Seprehvec™ huaketo oncolytic (Tumor Too; Tumor CNS) PH I BCMA ADC (Tumo Wai) Tuhinga o mua Bevacizumab-ADNAB™ (Te mate pukupuku Endometrial) Ph I Bevacizumab-ADNAB™ (Te mate pukupuku ovarian) Ph I Rituximab-ADNAB™ (Rumoma-a-B) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Papatono Matua (tohu)	Waahi
ZTlido® 1.8 orau (Postherpetic Neuralgia - PHN) Whakaaetanga FDA Gloperba® 1.8 orau Te maimoatanga o te kauti (waha) Whakaaetanga FDA SEMDEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Naltrexone Te Putanga Iti Te Putanga) Tuhinga o mua RTX (resiniferatoxin) Werohia epidural Ph II RTX (resiniferatoxin) Te ara-a-roto Ph II

Tukunga Lymphatic
Papatono Matua (tohu)	Wahanga II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I